Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5624_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
15.09.2026
Размер:
17 Мб
Скачать
☆
(DBU)[177] and then Wilson etal. using the phosphazine base 2-tert-butylimino-2-dieth-
(a)
(b)
ylamino-1,3-dimethylperhydro-1,3,2-diazaphosphorine (BEMP)[178], enabling [
11
C]CO2 to react rapidly under mild reactions conditions without the need for specialised laboratory apparatus (Figure7.17b). This chemistry was applied to carbonyl­via reaction of aliphatic primary[177] and secondary[178] amines with [
11
C-carbamate synthesis
11
C]CO2 in the presence of an alkylating agent in good RCY. Anilines, however, proved to be more chal­lenging substrates. Biologically active molecules, including the serotonin-receptor antag-
11
onist [ deacetylase inhibitor [
C]metergoline[177], the κ-opioid agonist [11C]GR103545[178], and the histone
11
C]MS-275[179], have been radiolabelled using this technique.
RNH
2
Q
Bases (Q):
N
N
DBU
11
[
–90
C]CO
NEt
11
[
N
2
3
o
C
C]CO
N
N
P
N
BEMP
Figure 7.17
Reaction of amines

with [
2 in the

tion agents.
O
R
N
*
H
2
Q
POCl
3
O
R3Y
*
N
C O
R
O
Y
O
Q
*
Path
O
O
*
1
R
NH
2
R
Path
O
1
R
N
*
2
R
RNH
2
3
R
I
R
R
II
R3Y
O
QH
R
symmetrical
11
1
NH
2
R
11
O
R
NHN
*
H
C-ureas
O
1
O
N
*
2
R
C-carbamates
3
R
(c)
POCl
3
O
XH
R
or
1
X
N
*
2
R
11
C-ureas,
11
C-carbamates
3
R
O
1
R
O
P
Cl
O
N
*
Cl
2
R
1
R
or
*
N
C O
3
R
X = NR
O
O
N
O
*
H
H
[11C]metergoline
32–40% RCY
<185 GBq/µmol
F
C
O
Cl
N
H
Cl
N
N
O
N
O
N
*
O
[11C]GR103545
24–35% RCY
108–162 GBq/µmol
H N
O
*
O
[11C]CURB
19% RCY
93 GBq/µmol
3
OH
[11C]SL25.1188
12% ndc RCY
37 GBq/µmol
O
N
O
N
*
O
OMe
 165
When evaluating DBU and BEMP as xation agents, Wilson etal. found that the latter
HPLC
MFC (N
MFC (N2, 2 Bar)
oered superior [
11
C]CO2 trapping and product yields, allowing 11C-carbamate formation to proceed at room temperature in approximately one minute[178]. Mechanistically, there are two possible reaction pathways following the formation of the base-[
11
C]carba­mate intermediate, depending on the order of the subsequent reactions with the amine and alkylating agent (Figure7.17b, Paths I and II). Investigating this, Wilson etal. obtained optimal product yields when the order of reagent addition was tailored to Path II ([
11
C]CO2 xation in the presence of the amine, followed by addition of alkylating agent), and that when this order was reversed, yields were very low[178].
In 2011, Wilson etal. extended this methodology to the synthesis of unsymmetrical carbonyl­ing agent POCl
11
C-ureas and carbonyl-11C-carbamates (Figure7.17c)[180] using the dehydrat-
to convert the 11C-carbamate intermediate into an 11C-isocyanate, which
3
can undergo reaction with a second amine or alcohol. Numerous PET tracers containing
11
[
C]carbamate[180–184] and 11C-urea[184–187] functional groups have been synthesized using this approach, including the clinically validated fatty acid amide hydrolase (FAAH) inhibitor [ previously only accessible in low yields from [
11
C]CURB[188] and the monoamine oxidase B (MAO-B) inhibitor [11C]SL25.1188,
11
C]phosgene[189].
This methodology was later transferred to an automated “in-loop” system consist­ing of three HPLC loops connected to an eight-port, two-way valve (Figure7.18)[190]. The loops are rst pre-loaded with reagent solutions: reactor loop A with amine and xation base; the reagent loop with the dehydrating agent, POCl
; and reactor loop B
3
with the second nucleophile (alcohol or amine). The reaction then proceeds in stages:
11
rst, [
11
reagent loop to form the reactor loop B, where it reacts with the nucleophile. The
C]CO2 is passed into and xed in reactor loop A to form the intermediate
C-carbamate ion, followed by the addition of POCl3 into reactor loop A from the
11
C-isocyanate. The 11C-isocyanate can then be eluted into
11
C-labelled product can then
Reagent loop
[11C]CO2 from target
V1
, 2 Bar)
2
Liquid nitrogen
Detector
Figure 7.18 2
Waste
Lift
V2
V3
Waste
AB
Reactor loop
Detector
Receiving
vial
Vent
Detector
John Wiley & Sons.
166 Handbook of Radiopharmaceuticals
be eluted into the receiving vial. [11C]SL25.1188 and two novel FAAH inhibitors were syn-
RN
2
R
2
R
1
20–80 oC
thesized using this method, and in all cases, non-isolated RCYs were higher than for the corresponding vial reactions.
Dheere etal. reported an alternative pathway to access symmetrical[191] and unsym-
metrical[192] carbonyl-
11
C-ureas, utilising the Mitsunobu reaction to facilitate reaction of poorly nucleophilic amines such as anilines (Figure7.19a). This reaction proceeds in three stages: (i) DBU-mediated [
11
C]CO2 xation to form a 11C-carbamate intermediate, (ii) addition of Mitsunobu reagents (tributylphosphine and di-t-butyl azodicarboxylate) to form an oxyphosphonium species, and (iii) reaction with a second amine upon gentle heating. This provides was later extended to the production of
11
C-ureas in high RCYs of 69–94%. The scope of this methodology
11
C-amides via reaction of the oxyphospho­nium intermediate with Grignard reagents (Figure7.19b) and applied to the synthesis the hormone [
11
C]melatonin[193]. In 2018, Downey etal. performed a proof-of-concept loop-based Mitsunobu radiolabelling reaction to synthesise the model compound N,N′-[carbonyl-
11
C]dibenzylurea with a RCY of 72%, in a process lasting only three min-
utes[194].
 ─
Base-mediated [11C]CO2 xation chemistry has also been exploited for 11C─C bond formation, providing a milder alternative to Grignard chemistry. This was rst reported in 2012 by Riss etal. using boronic esters to form carbonyl­a copper(I)-mediated process (Figure7.20)[195]. Boronic esters can be incorporated onto highly functionalised molecules and are less sensitive to moisture and oxygen than Grignard reagents, allowing for easier handling and storage. Tetramethylethylene­diamine (TMEDA), acting as both xation agent and chelating ligand for copper, was identied as the optimal base, providing near-quantitative [ yields for a broad range of functionalised
11
C-carboxylic acids, with electron-decient and amino-substituted aromatics being the most challenging substrates. acids could be further derivatised in a one-pot process using alkylating, chlorinating, or coupling agents (Figure7.20a–c), as exemplied by the synthesis an oxytocin receptor ligand[195], the retinoic acid X receptor agonist [ agonist [ 3-hydroxycyclopent-1-ene-[
11
C]AH-7921[197], and a ligand for γ-hydroxybutyric acid (GABA) binding sites
11
C]carboxylic acid[198].
11
C]bexarotene[196], the μ-opioid
11
C-carboxylic acids through
11
C]CO2 trapping and high
11
C-Carboxylic
Figure 7.19 [2
R
 subsequent Mitsu
1
R
nobu reaction to form [

[
C]amides.
1

C]ureas and
(a)
11
[
C]CO
H
2
2
DBU
O
R
N
O
*
H
PBu
DBAD
3
O
R
PBu
N
*
H
3
O
(b)
N H
50 oC
R1MgBr
R
R
O
NHN
*
O
NHR
*
 167
O
Figure 7.20 
mediated


carboxylation of boronic esters and subsequent deriva tisation reactions.
CH3I, TMEDA
(a)
R
O B
O
R
[11C]CO
R
CuI, TMEDA
crypt–222, KF
100
2
o
C
R
O
OH
*
(b)
(c)
1.
SOCl
2
HN
2.
1. Diisopropyl­cabodiimide
2. DMAP, NHS
O
F
CH
3
O
*
O
N
*
O
O
O
N
O
*
O
O
OH
*
N
*
O
oxytocin ligand
20% RCY
56 GBq/µmol
O
N
*
H
O
F
[11C]AH–7921
~200 GBq/µmol
N
1–2% RCY
HO
[
831–1012 MBq
1. 5 GBq/µmol
11
C]HOCPCA
O
OH
*
11
[
C]bexarotene
15% RCY
>11 GBq/µmol
7.4.2 Reactions with [11C]CO
[11C]CO was one of the very rst 11C radiotracers to be investigated in humans[7]; yet despite its ease of production and the prevalence of the carbonyl group in biologi­cally relevant molecules, it was not exploited as a radiolabelling reagent until relatively recently due to the challenges associated with its handling and reactivity. The poor solu­bility of CO in common organic solvents means conventional carbonylations are typically performed using a large stoichiometric excess of CO and often require high tempera­tures, elevated pressures, and extended reaction times; conditions that are dicult to achieve with low-mass, low-concentration [ the use of stoichiometric catalyst loadings, favouring increased reaction rates and fast conversions.
The palladium(0)-catalysed Heck carbonylation[199, 200], which couples an electro­phile and a nucleophile with CO, has been extensively investigated for due to its compatibility with a wide range of nucleophilic substrates (Figure7.21). Early attempts involved Stille-type coupling of organotin reagents and aryl halides to generate carbonyl­(Figure7.21a)[201–203]. While
11
C-ketones, following delivery of [11C]CO at atmospheric pressure
11
C-ketones were generally produced in high radiochemical purity, RCYs were low (~10%), with the majority of [ solution. The principal challenge in sucient quantities of [
11
C]CO into solution in order to react. Over the years, a number of
11
technological and chemical approaches have been developed to overcome this problem.
11
C]CO. These conditions, however, allow for
11
C-radiolabelling
11
C]CO passing unreacted through the
C-carbonylation chemistry, therefore, is to transfer
168 Handbook of Radiopharmaceuticals
Ar
R
(a)
*
*
(b)
R-SnMe
or R-B(OH)
R2NH
Figure 7.21 Scope
2
R

1
catalysed


Ar
O
*
3
2
R
1. R1R2NH
2.NaBH
3
CN
Ar
N
*
R
reactions.
O
Ar N
R
*
R
(c)
11
[
X
C]CO
L
n
Pd
0
(d)
(e)
(f)
Et3SiH
ROH
OH
–
Cl
–
O
Ar H
*
O
Ar
*
O
Ar
*
O
O
OH
R
–
Nu
Ar
Cl
Ar Nu
 
Preconcentrating [11C]CO on a liquid-nitrogen-cooled silica trap prior to delivery to the reaction media has been reported to increase [ 30–40%[204, 205]. A gas-handling system in which [ reagent solution leads to a further improvement, enabling 36–62% RCY[204].
11
C]CO incorporation to around
11
C]CO is recirculated through the
11
C-ketones to be obtained in
H
O
 
An alternative means of increasing [11C]CO solubility is to increase the gas pressure within a sealed vessel. To achieve this, Långström etal. developed a micro-autoclave reactor capable of performing peratures (~200 °C) (Figure7.22)[207]. In this process, preconcentrated [ ferred into the micro-autoclave chamber; the coupling reagent solution is then added using an HPLC pump that compresses the gas to <2% of the liquid volume, thus producing a pseud one-phase system[208, 209]. An alternative high-pressure reactor was reported
11
C-carbonaylations at high pressures (~35 MPa, 350 atm) and tem-
11
C]CO is trans-
 169
Figure 7.22 

autoclave reaction system. Source:
 
Wiley & Sons.
in 2002, in which the reactant solution is pushed through the [11C]CO trapping loop and into the microreactor[210].
The micro-autoclave was initially used for the synthesis of carbonyl-
11
C-amides in good RCY and with excellent molar activity via Pd(0)-catalysed reaction of aryl halides and amines with [
11
C]CO[211], and has since been used to prepare 11C-radiolabelled ketones, amides, aldehydes, esters, carboxylic acids, and derivatives such as amines, alkyl iodides, and acyl chlorides (Figure7.21a–e)[23, 209].
In 2017, Dahl and Nordeman reported the direct synthesis of carbonyl-
chlorides via Pd(0)-catalysed
11
C-benzoyl chloride could undergo further reactions with various nucleophiles to form
the corresponding
11
C-labelled carboxylic acids, amides, esters, or aldehydes as well
11
C-carbonylation of aryl halides (Figure7.21f)[212]. The
11
C-benzoyl
as alcohols and ketones[213]. In 2017, Altomonte etal. reported that the use of reac­tive diaryliodonium salts in place of aryl halides in the Heck
11
C-carboxylic acids and 11C-amides to be formed at room temperature[214].
High-pressure
11
C-carbonylations have been used to radiolabel numerous drug-like
11
C-carbonylation enabled
molecules, as shown in Figure7.23[215], including the α-amino-3-hydroxy-5-methyl-4­isoxazolepropionic acid (AMPA) receptor modulator [
11
[
C]FIMX[216], the translocator protein 18 kDa (TSPO) receptor ligands 11C-PK11195[217]
11
and [
C]DAA1106[218], the AT1 receptor ligand [11C]eprosartan[219], the β-secretase 1
(BACE-1) inhibitor [
11
C]BSI-IV[220], histamine H3R ligands[221], the histone deacetylase
11
C]CX546[210], the mGluR1 ligand
170 Handbook of Radiopharmaceuticals
O
N
O
455 GBq/µmol
O
11
C]CX546
[
Pd(PPh
37% RCY
4–19 GBq/µmol
O
O
S
N
*
HN
O
[11C]BSI-IV
Pd(xantphos)Cl
29% RCY
4–19 GBq/µmol
Figure 7.23 
radioligands synthesised via
 


reactions.
N
O
*
C]MK-0233
Pd(PPh
NH
N
F
3)4
N
O
N
*
N
O
S
N
*
F
11
C]FIMX
[
3)4
Pd(PPh 37% RCY
3)4
NH
N
O
11
[
Human PET study
100 GBq/µmol
O
OH
S
N
3)4
HN
HO
NH
Ph
O
[
2
393 GBq/µmol
N
11
C]PK11195
Pd(PPh 55% RCY
O
N
*
Cl
O
*
OH
N
[11C]eprosartan
3)4
Pd(PPh
37–54% RCY
360 GBq/µmol
O
N
O
Histamine H3R ligand
(dba)3/P(o-tol)
Pd
2
9% RCY
398 GBq/µmol
O
*
F
O
F
*
N
N
O
O
F
3
OPh
[11C]DAA1106
Pd(PPh
3)4
30% RCY
[11C]tubastatin A
Pd
N
(dba)3/xantphos
2
16% RCY
8 GBq/µmol
OH
N
*
H
6 inhibitor [11C]tubastatin-A[222], and the neuropeptide Y5 receptor antagonist [11C] MK-0233[223, 224], which has been studied in humans[225]. Aberg and Långström used this approach to synthesise a library of 12 potential irreversible epidermal growth factor receptor (EGFR) inhibitors from 4 substituted vinyl iodides and 3 dierent amino-quinaz­olines through Pd(0)-catalysed
11
C-carbonylation reactions using a single set of reaction conditions[226]. A semi-automated dispensing system for performing multiple carbonyl­ation reactions with a single batch of [ and may facilitate combinatorial
11
C]CO has been developed by Van der Wildt etal.
11
C-radiolabelling strategies[227].
 171
The scope of the micro-autoclave system has been explored beyond Pd(0)-catalysis.
O
Nu
11
C-Labelled ureas[228–231] and carbamates[228] have been produced by Rh(I)­catalysed radiolabelling (Figure7.24). This reaction is thought to proceed via an
11
C-carbonylation of azides, providing an alternative to [11C]CO2 or [11C]COCl2
11
C-isocyanate
intermediate, which can then react with a nucleophile to generate the corresponding
11
C-carbonyl compound. A carbonyl-11C-malonate has been produced using a diazo starting material instead of an azide. This could be further functionalised at the α-carbonyl position by deprotonation and reaction with an alkylating agent[232]. Rh(I)-catalysed
11
C-carbonylations have been used to synthesise bioactive molecules such as the cyto­toxic sulfonylurea [
11
C]LY-181984[231], the Pgp substrate [11C]phenytoin[24], and a dual vascular endothelial growth factor receptor-2/platelet-derived growth factor receptor β (VEGFR-2/PDGFRβ) inhibitor[230].
The transition metal-catalysed reactions described so far are limited to methyl, benzyl, aryl, and vinyl halides as the electrophilic coupling partner to avoid competing β-hydrogen elimination at the metal centre following oxidative addition. To extend the labelling of aliphatic substrates, Långström etal. explored metal-free photoinitiated
11
radical with a sapphire window to allow irradiation of UV light to prepare
C-carbonylations of alkyl iodides using a modied micro-autoclave equipped
11
C-labelled aliphatic amides[233, 234], esters[234–236], and carboxylic acids[208, 236–238] (Figure7.25a). Reactions generally proceeded in good RCY, although in some cases photosensitis­ers such as acetone, benzophenone, or di-t-butyl peroxide were added to improve yields[234, 236].
Selenium-catalysed high-pressure
11
C-carbonylations have also been investigated for the conversion of amines, amino alcohols, and alcohols into cyclic and acyclic carbonyl-
11
C-ureas, carbonyl-11C-carbamates, and carbonyl-11C-carbonates, respectively
(Figure7.25b)[239]. These reactions are thought to proceed via initial formation of
11
[
C]carbonyl selenide, which can then undergo reaction with an amine to produce an
intermediate
11
C-isocyanate. Subsequent nucleophilic attack of the isocyanate yields the
Figure 7.24
 
alysed


bonylation to
[11C]CO
N
3
RhL
n
– N
2
form carbamyl derivatives.
H N
*
S
O
O
O
[11C]LY- 181984
[Rh(cod)Cl]
68% RCY
H N
, PPh
2
172 Handbook of Radiopharmaceuticals
11
C
III
Rh
N
Cl
3
L
n
HN
*
O
[11C]phenytoin
Rh
(OAc)4, DPPE
2
22% RCY
277 GBq/µmol
O
NH
VEGFR-2/PDGFR inhibitor
O
11
C
N
N
O
O
O
F NHN
[Rh(cod)Cl]
O
*
, PPh
2
78% RCY
92 GBq/µmol
Nu
F
H
3
O
11
C
N H
RI
′
(a)
11
[
C]CO
hv
H
O
2
R′-OH
O
R
OH
*
O
R′
R
O
*
OH
73% RCY
O
O OH
188 GBq/µmol
*
O
O
*
61% RCY 158 GBq/µmol
Figure 7.25 



reactions to form

[
C]carbonyl
compounds.
O
N
*
N
Ph
54% RCY 192 GBq/µmol
R′-NH
2
O
R N
*
R′
H
(b)
Se
11
[
C]CO
Se
R-NH
– SeH2
O
2
R
N
O
[11C]SBox-13
44% RCY
O
*
C
N
N
*
O
O
*
C
Ph
R-XH
CN
R
O
NHX
corresponding 11C-carbamoyl product. This method was used to synthesise the oxazolidi­none MAO-B radioligand [
11
C]SBox-13, previously accessed via [11C]COCl2.
 
Despite the success of high-pressure 11C-carbonylation, its technical complexity and lack of commercial availability have prompted researchers to explore alternative approaches. In 2004, Audrain etal. reported on the use of BH enhance [
11
C]CO solubility at atmospheric pressure via coordination of BH3 to the lone electron pair of CO[240]. This process was used to synthesise a model carbonyl­and model carbonyl-
11
C-lactone in moderate RCY via Pd(0)-catalysed 11C-carbonylation. In
2009, Kealey etal. used a copper(I) tris(pyrazolyl)borate (CuTp*) complex to coordinate
11
[
C]CO, observing near-quantitative [11C]CO trapping at room temperature without the
need for a preconcentration step[241]. [
11
C]CO was released by addition of a competing phosphine ligand and used directly in a one-pot Pd(0)-catalysed form model carbonyl­NPY-Y5 radioligand [
11
C-amides and carbonyl-11C-carboxylic acids[241–243], including the
11
C]MK-0233 (Figure7.26)[244].
•THF as a complexation agent to
3
11
C-carbonylation to
11
C-amide
R
 173
O
O
48% RCY
N
*
H
N–benzyl[carbonyl-11C]benzamide
: 47% RCY
via BH
3
via Cu(I): 67% RCY
via xenon: 71% RCY
via Pd-xantphos: 98% RCY
Ph
N
O
N
*
H
VAChT ligand
via xenon
9% RCY
55–78 GBq/µmol
N
OH
NH
N
O
*
O
[11C]MK-0233
via Cu(I) 7% RCY
100 GBq/µmol
H
Ph
Ph
11
[
C]N-tritylacrylamide
via xenon/Pd-xantphos
86–170 GBq/µmol
N
*
Ph
O
22% RCY
N
F
i
Bu
S
S
O
[11C]C21
via xenon 24% RCY
34–51 GBq/µmol
O
N
N
H
receptor ligand
3
via Pd-xantphos
88% RCY
121 GBq/µmol
N
N
O
O
N
OBu
*
H
O
*
NH
O
Ph
Cl
O
N
*
H
N
N
N H
TG2 inhibitor
via xenon
38–45% RCY
220 GBq/µmol
O
O
N
*
H
OH
Cl
[11C]raclopride
via Pd-xantphos
50% RCY
34 GBq/µmol
N
N
O
N
N
N
cyclo-RGD
[11C]lactone-cycloRGD
bioconjugate
via Pd-xantphos
O
*
O
N
O
*
H
11
[
C]JNJ-31020028
via Ar-Pd-xantphos
25% RCY
N
FN
O
N
Ph
N
Figure 7.26 
ation methods.
During these experiments, it was observed that replacing the Pd(0) with a Pd(II) species led to the formation of homocoupled N,N′-[carbonyl­side product. This reaction was further developed for the synthesis of
11
C]dibenzylurea as a major
11
C-labelled sym­metrical and unsymmetrical ureas (Figure7.27a). Urea formation is thought to proceed via a Pd(II)-mediated oxidative carbonylation process, as previously reported using
174 Handbook of Radiopharmaceuticals